How Fusobacterium nucleatum Travels Through the Body and Finds Tumours

There is a genuinely substantial body of non-oncology research here — and it carries particular weight given how many metastatic breast cancer members are also managing bone health concerns, on bone-protective medications, or watching for skeletal metastases. This intersects powerfully with what was already laid out about bone metastases.

Fusobacterium nucleatum and Bone Disease Outside of Cancer

It Physically Infects Bone — This Is Documented, Not Theoretical

Clinical case reports going back decades — and now accumulating into a pattern — confirm that Fusobacterium nucleatum can cause osteomyelitis (direct infection and destruction of bone tissue) through the bloodstream route, originating from periodontal disease. Cases have been documented in the fibula, femur, ileum, hip, foot, hand, vertebrae, thumb, and skull — and critically, in otherwise immunocompetent adults with no known risk factors other than recurrent periodontal disease. In every case, periodontitis was identified as the presumed source of bacteremia that seeded the bone.

A 2012 case that received significant citation in the literature involved a healthy 59-year-old man who developed osteomyelitis of the fibula with a surrounding muscle abscess — cultures from multiple tissue specimens confirmed Fusobacterium nucleatum as the organism, and the clinical team concluded that recurrent periodontitis drove hematogenous seeding to a distant skeletal site. A 2015 paediatric case series documented three previously healthy children developing Fusobacterium nucleatum osteomyelitis in skull, facial, and long bones — all with oral infection as the source. A concurrent long-bone osteomyelitis and lung empyema case confirmed via 16S rRNA gene sequencing further established that Fusobacterium nucleatum can simultaneously infect bone and other tissue from a single oral source.

These are rare as acute clinical events — but they establish beyond doubt that Fusobacterium nucleatum has the biological capacity to travel from the mouth to bone via the blood and cause direct structural damage. The acute osteomyelitis cases represent the visible extreme of a spectrum; what the cellular biology research is showing is that far subtler, chronic effects on bone biology are happening at lower bacterial exposure levels.

What Fn Does to Bone-Building Cells

This is perhaps the most important non-oncology finding for your group, given the intersection with cancer treatment bone effects. A 2020 study — the first to evaluate long-term Fusobacterium nucleatum interaction with osteoblasts (the cells that build and maintain bone) — found the following across multiple lines of cellular biology evidence:

• Fusobacterium nucleatum inhibits osteoblast cell proliferation — fewer new bone-building cells are produced

• It promotes osteoblast apoptosis — it kills the bone-building cells that already exist

• It elevates pro-inflammatory cytokine production inside osteoblasts — turning bone-building cells into inflammation generators

• It blocks osteoblast differentiation — immature bone precursor cells cannot mature into functional bone-builders

• It suppresses mineralised nodule formation — the physical calcification process that gives bone its structural density is impaired

• It reduces expression of osteogenetic genes including alkaline phosphatase, collagen-1, and osteocalcin — the molecular machinery of bone formation is shut down

Transcriptome analysis (looking at which genes are switched on or off) identified 235 differentially expressed genes across all time points — the overwhelming majority were inflammation-related. The researchers also noted that this long-term bacterial-induced cellular stress could potentially increase the risk of malignant transformation in osteoblasts — a finding that connects back directly to the cancer context.

A 2024 study extended this further, showing that Fusobacterium nucleatum infection under biomechanical loading conditions — the kind your bones experience in daily movement — elevates prostaglandin E2 and cyclooxygenase-2, disrupts the RANKL-to-osteoprotegerin ratio (the master regulatory balance between bone destruction and bone formation), and accelerates alveolar bone destruction. This RANKL/OPG imbalance is the same mechanism that drives bone metastasis destruction in cancer — the signalling language is shared.

Rheumatoid Arthritis: A Direct Worsening Effect

Research has confirmed that Fusobacterium nucleatum is enriched in the gut microbiome of rheumatoid arthritis patients compared to healthy controls, and is positively correlated with disease severity — meaning more Fusobacterium nucleatum burden corresponds to worse joint disease. A dedicated mechanistic study showed that Fusobacterium nucleatum outer membrane vesicles — the same molecular parcels discussed in the cancer sections — directly aggravate rheumatoid arthritis by delivering inflammatory cargo into joint-associated immune cells. This is not a passive correlation; the OMVs are actively worsening joint inflammation through the same NF-κB and TLR4 pathways seen in tumour tissue.

A separate case report confirmed Fusobacterium nucleatum as the direct causative organism in septic arthritis in an immunocompetent patient — again, originating from the oral cavity via hematogenous spread.

Why This Matters Specifically for Metastatic Breast Cancer Members

For members in this group, the non-oncology bone biology of Fusobacterium nucleatum compounds the cancer picture in several converging ways:

Bone-protective medications interact with an already disrupted system. Bisphosphonates (zoledronic acid, denosumab) work by suppressing osteoclast activity to protect bone in metastatic disease. If Fusobacterium nucleatum is simultaneously suppressing osteoblast function and activating RANKL-driven osteoclast activity from a periodontal source, the medication is working against a bacterial headwind that is not being addressed. Treating the oral source is a logical complement to skeletal protective therapy — not an alternative to it.

The jaw osteonecrosis risk from bisphosphonates is directly relevant here. Medication-related osteonecrosis of the jaw (MRONJ) is one of the most significant and feared complications of long-term bisphosphonate use in cancer patients. Fusobacterium nucleatum is consistently among the organisms cultured from MRONJ lesions — its bone-invasive capacity via periodontal pockets in a jaw already metabolically compromised by bisphosphonates creates precisely the conditions for this complication. Rigorous periodontal management before and during bisphosphonate therapy is the established prevention strategy — and this is the bacterium that makes that prevention non-negotiable.

Bone density loss during cancer treatment is multifactorial — but Fn is one factor. Aromatase inhibitors, chemotherapy-induced ovarian failure, and corticosteroid use all reduce bone density. The additional osteoblast suppression and RANKL/OPG disruption driven by Fusobacterium nucleatum colonisation is a potentially modifiable contributor to treatment-related bone loss that has not yet been formally studied in breast cancer patients — but the cellular mechanism is clearly established.

References:

1. Lee MJ et al., Osteomyelitis of a long bone due to Fusobacterium nucleatum associated with periodontitis, BMC Infectious Diseases, 2012. PMC3481430

2. Gregory SW et al., Fusobacterium nucleatum Osteomyelitis in 3 Previously Healthy Children, Open Forum Infectious Diseases, 2015. PMC4681383

3. IMJ Case Report, Concurrent Long Bone Osteomyelitis and Empyema Caused by Fusobacterium nucleatum, Irish Medical Journal, 2020. DOI: imj.ie

4. Wang Z et al., The Pathogenic Effects of Fusobacterium nucleatum on Osteoblasts: An In Vitro Study, Frontiers in Cellular and Infection Microbiology, 2020. PMC7517582

5. Teixeira MKS et al., Fusobacterium nucleatum mechanism of action in alveolar bone destruction, Frontiers in Oral Health, 2024. PMC11684578

6. Anonymous, Fusobacterium nucleatum aggravates rheumatoid arthritis through outer membrane vesicles, Rheumatology & Autoimmunity, 2024. DOI: 10.1002/rai2.12093

7. Anaya-Sanchez A et al., Septic arthritis due to Fusobacterium nucleatum in an immunocompetent patient, Reumatología Clínica, 2012. PMID: 22089068

8. First case of calcaneal Brodie's abscess caused by Fusobacterium nucleatum, Journal of Bone and Joint Infection, 2025. DOI: 10.1016/j.jbji.2025